Metformin inhibits food intake and neuropeptide Y gene expression in the hypothalamus

Metformin may reduce food intake and body weight, but the anorexigenic effects of metformin are still poorly understood. In this study, Sprague-Dawley rats were administered a single intracere-broventricular dose of metformin and compound C, in a broader attempt to investigate the regula-tory effects of metformin on food intake and to explore the possible mechanism. Results showed that central administration of metformin significantly reduced food intake and body weight gain, par-ticularly after 4 hours. A reduction of neuropeptide Y expression and induction of AMP-activated protein kinase phosphorylation in the hypothalamus were also observed 4 hours after metformin administration, which could be reversed by compound C, a commonly-used antagonist of AMP-activated protein kinase. Furthermore, metformin also improved lipid metabolism by reducing plasma low-density lipoprotein. Our findings suggest that under normal physiological conditions, central regulation of appetite by metformin is related to a decrease in neuropeptide Y gene expres-sion, and that the activation of AMP-activated protein kinase may simply be a response to the anorexigenic effect of metformin.

[1]  M. Vega,et al.  Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients. , 2013, Human reproduction.

[2]  S. Hayashi,et al.  Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs , 2013, Clinical toxicology.

[3]  B. Viollet,et al.  Revisiting the mechanisms of metformin action in the liver. , 2013, Annales d'endocrinologie.

[4]  Lixin Liu,et al.  The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats , 2013, Cardiovascular Diabetology.

[5]  A. López-Bermejo,et al.  Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity. , 2013, The Journal of clinical endocrinology and metabolism.

[6]  A. Eynard,et al.  Overweight and obesity: a review of their relationship to metabolic syndrome, cardiovascular disease, and cancer in South America. , 2013, Nutrition reviews.

[7]  U. Werneke,et al.  Behavioral Interventions for Antipsychotic Induced Appetite Changes , 2013, Current Psychiatry Reports.

[8]  N. Gilpin.  Neuropeptide Y (NPY) in the extended amygdala is recruited during the transition to alcohol dependence , 2012, Neuropeptides.

[9]  A. Inui,et al.  Metformin and incretin-based therapies up-regulate central and peripheral Adenosine monophosphate-activated protein affecting appetite and metabolism , 2012, Indian journal of endocrinology and metabolism.

[10]  K. Won,et al.  Intracerebroventricular Injection of Metformin Induces Anorexia in Rats , 2012, Diabetes & metabolism journal.

[11]  P. Ročić,et al.  The Metabolic Syndrome, Oxidative Stress, Environment, and Cardiovascular Disease: The Great Exploration , 2012, Experimental diabetes research.

[12]  J. McGill.  Pharmacotherapy in type 2 diabetes: a functional schema for drug classification. , 2012, Current diabetes reviews.

[13]  Jun-ping Wen,et al.  The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats , 2012, Brain Research.

[14]  B. Viollet,et al.  Cellular and molecular mechanisms of metformin: an overview. , 2012, Clinical science.

[15]  V. Trajković,et al.  Intracerebroventricular Administration of Metformin Inhibits Ghrelin-Induced Hypothalamic AMP-Kinase Signalling and Food Intake , 2012, Neuroendocrinology.

[16]  Z. Żukowska,et al.  NPY and Stress 30 Years Later: The Peripheral View , 2012, Cellular and Molecular Neurobiology.

[17]  N. Kimura,et al.  A Novel Cardioprotective Agent in Cardiac Transplantation: Metformin Activation of AMP-Activated Protein Kinase Decreases Acute Ischemia-Reperfusion Injury and Chronic Rejection , 2011, The Yale journal of biology and medicine.

[18]  W. Colmers,et al.  The role of NPY in hypothalamic mediated food intake , 2011, Frontiers in Neuroendocrinology.

[19]  Shraddha V. Bhadada,et al.  Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats. , 2011, European journal of pharmacology.

[20]  B. Viollet,et al.  AMP-activated protein kinase (AMPK) activity is not required for neuronal development but regulates axogenesis during metabolic stress , 2011, Proceedings of the National Academy of Sciences.

[21]  S. Moenter,et al.  Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood. , 2011, Endocrinology.

[22]  A. Kiss,et al.  Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. , 2010, Biochemical and biophysical research communications.

[23]  K. Kyuki,et al.  Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. , 2010, Biological & pharmaceutical bulletin.

[24]  D. Allison,et al.  Metformin supplementation and life span in Fischer-344 rats. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.

[25]  M. Driscoll,et al.  Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1 , 2010, PloS one.

[26]  A. Comlekçi,et al.  Soluble CD40 Ligand, Plasminogen Activator Inhibitor-1 and Thrombin-Activatable Fibrinolysis Inhibitor-1-Antigen in Normotensive Type 2 Diabetic Subjects without Diabetic Complications , 2009, Medical Principles and Practice.

[27]  Huaxi Xu,et al.  Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription , 2009, Proceedings of the National Academy of Sciences.

[28]  V. Anisimov,et al.  Metformin slows down aging and extends life span of female SHR mice , 2008, Cell cycle.

[29]  Haiying Cheng,et al.  Key Role for AMP-Activated Protein Kinase in the Ventromedial Hypothalamus in Regulating Counterregulatory Hormone Responses to Acute Hypoglycemia , 2008, Diabetes.

[30]  In-kyu Lee,et al.  Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHP , 2008, Diabetes.

[31]  F. Pralong,et al.  Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. , 2007, Endocrinology.

[32]  M. Suwa,et al.  Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. , 2006, Journal of applied physiology.

[33]  P. Barrett,et al.  Negative energy balance and leptin regulate neuromedin-U expression in the rat pars tuberalis. , 2006, The Journal of endocrinology.

[34]  G. Ronnett,et al.  Developing a head for energy sensing: AMP‐activated protein kinase as a multifunctional metabolic sensor in the brain , 2006, The Journal of physiology.

[35]  B. Xue,et al.  AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues , 2006, The Journal of physiology.

[36]  J. Huh,et al.  Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. , 2006, Diabetes.

[37]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[38]  A. Iguchi,et al.  Metformin ameliorates treatment of obese type 2 diabetic patients with mental retardation; its effects on eating behavior and serum leptin levels. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[39]  R. Palmiter,et al.  Neuropeptide Y is required for hyperphagic feeding in response to neuroglucopenia. , 2004, Endocrinology.

[40]  J. Hagan,et al.  Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats , 2004, Psychopharmacology.

[41]  M. Birnbaum,et al.  AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus , 2004, Nature.

[42]  S. Del Prato,et al.  Reducing insulin resistance with metformin: the evidence today. , 2003, Diabetes & metabolism.

[43]  R. Huupponen,et al.  Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. , 2003, Diabetes.

[44]  D. Hardie,et al.  The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. , 2002, Diabetes.

[45]  Olle Ljunqvist,et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.

[46]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[47]  C. Glueck,et al.  Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. , 2001, Metabolism: clinical and experimental.

[48]  J. Roberts,et al.  Adrenalectomy reverses obese phenotype and restores hypothalamic melanocortin tone in leptin-deficient ob/ob mice. , 2000, Diabetes.

[49]  L. V. D. van der Ploeg,et al.  Evidence of altered hypothalamic pro-opiomelanocortin/ neuropeptide Y mRNA expression in tubby mice. , 1998, Brain research. Molecular brain research.

[50]  Paolisso,et al.  Effect of metformin on food intake in obese subjects , 1998, European journal of clinical investigation.

[51]  S. Dryden,et al.  Increased neuropeptide Y secretion in the hypothalamic paraventricular nucleus of obese (fa/fa) Zucker rats , 1995, Brain Research.

[52]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[53]  R. Huupponen,et al.  Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y. , 1995, European journal of pharmacology.

[54]  S. Svacina.  Treatment of obese diabetics. , 2012, Advances in experimental medicine and biology.

[55]  D. Ehrmann,et al.  Targeting the Consequences of the Metabolic Syndrome in the Diabetes Prevention Program , 2012 .

[56]  D. Judge.  AMP-activated protein kinase regulates neuronal polarization by interfering with PI 3-kinase localization , 2011 .

[57]  A. Golay.  Metformin and body weight , 2008, International Journal of Obesity.

[58]  J. Park,et al.  Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. , 2005, Diabetes.

[59]  J. Reckless,et al.  Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. , 2004, Diabetes care.

[60]  R. Palmiter,et al.  Response of melanocortin–4 receptor–deficient mice to anorectic and orexigenic peptides , 1999, Nature Genetics.

[61]  J. Flier,et al.  Characterization of expression of hypothalamic appetite-regulating peptides in obese hyperleptinemic brown adipose tissue-deficient (uncoupling protein-promoter-driven diphtheria toxin A) mice. , 1998, Endocrinology.